Expression of WT1 Protein and Correlation With Cellular Proliferation in Glial Tumors

Hashiba, Tetsuo; Izumoto, Shuichi; Kagawa, Naoki; Suzuki, Tsuyoshi; Hashimoto, Naoya; Maruno, Motohiko; Yoshimine, Toshiki

doi:10.2176/nmc.47.165

Cited by 49 publications

(44 citation statements)

References 26 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WT1 expression was detected in 70 (95.9%) of 73 glial tumors examined. 12 Targeting WT1 may be particularly appropriate, because WT1 is expressed frequently in glioma tissue and is highly immunogenic for adaptive antitumor immune responses. 6,29,41 The timing of administration is another important factor.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma

Sakai

Shimodaira

Maejima³

et al. 2015

JNS

View full text Add to dashboard Cite

abbreviatioNs CTL = cytotoxic T lymphocyte; DC = dendritic cell; HLA = human leukocyte antigen; IL = interleukin; Ke = kiloequivalent; KPS = Karnofsky Performance Scale; MST = median overall survival time; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease; TAA = tumor-associated antigen; WT1 = Wilms' tumor 1. Department of Neurosurgery, National Hospital Organization, Shinshu Ueda Medical Center, Ueda, Nagano, Japan obJect Dendritic cell (DC)-based vaccination is considered a potentially effective therapy against advanced cancer. The authors conducted a Phase I study to investigate the safety and immunomonitoring of Wilms' tumor 1 (WT1)-pulsed DC vaccination therapy for patients with relapsed malignant glioma. methods WT1-pulsed and/or autologous tumor lysate-pulsed DC vaccination therapy was performed in patients with relapsed malignant gliomas. Approximately 1 × 10 7 to 2 × 10 7 pulsed DCs loaded with WT1 peptide antigen and/or tumor lysate were intradermally injected into the axillary areas with OK-432, a streptococcal preparation, at 2-week intervals for at least 5-7 sessions (1 course) during an individual chemotherapy regimen. results Ten patients (3 men, 7 women; age range 24-64 years [median 39 years]) with the following tumors were enrolled: glioblastoma (6), anaplastic astrocytoma (2), anaplastic oligoastrocytoma (1), and anaplastic oligodendroglioma (1). Modified WT1 peptide-pulsed DC vaccine was administered to 7 patients, tumor lysate-pulsed DC vaccine to 2 patients, and both tumor lysate-pulsed and WT1-pulsed DC vaccine to 1 patient. The clinical response was stable disease in 5 patients with WT1-pulsed DC vaccination. In 2 of 5 patients with stable disease, neurological findings improved, and MR images showed tumor shrinkage. No serious adverse events occurred except Grade 1-2 erythema at the injection sites. WT1 tetramer analysis detected WT1-reactive cytotoxic T cells after vaccination in patients treated with WT1-pulsed therapy. Positivity for skin reaction at the injection sites was 80% (8 of 10 patients) after the first session, and positivity remained for these 8 patients after the final session. coNclusioNs This study of WT1-pulsed DC vaccination therapy demonstrated safety, immunogenicity, and feasibility in the management of relapsed malignant gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The WT1 gene encodes a transcription factor that controls the transcription of various genes and is overexpressed in a variety of hematological malignancies and solid tumors, including gliomas. 12,27 WT1 may be a target antigen for immunotherapy against these cancers.…”

mentioning

confidence: 99%

Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma

Sakai

Shimodaira

Maejima³

et al. 2015

JNS

View full text Add to dashboard Cite

show abstract

“…It is also over expressed in several solid tumors (Inoue et al, 1997;Oji et al, 1999;Miyoshi et al, 2002a;Oji et al, 2002;Keilholz et al, 2005), and therefore, has been considered as an attractive target for cancer immunotherapy. In addition, WT1 gene expression increases in various types of blood malignancies (ZamoraAvila et al, 2007;Wagner et al, 2008) and different carcinomas such as lung, thyroid, breast (Zapata-Benavides et al, 2002;Caldon et al, 2008), testis (Hashiba et al, 2007), and ovary (Shimizu et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Wilms' Tumor Gene (WT1) Expression Correlates with Vascular Epithelial Growth Factor (VEGF) in Newly Acute Leukemia Patients Undergoing Chemotherapy

Iranparast¹,

Assarehzadegan²,

Heike³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Today, leukemia is one of the biggest problems worldwide. The Wilms' tumor gene (WT1) and the vascular endothelial growth factor (VEGF) gene are highly expressed in patients with various cancers. This study concerned the relationship between expression of WT1 and VEGF in patients with acute leukemia. Materials and Methods: We evaluated expression of WT1 mRNA and VEGF mRNA using real-time quantitative RT-PCR in the peripheral blood (PB) of 8 newly diagnosed AML and 4 newly diagnosed ALL patients, serially monitored for 2 months. A further 12 normal PB samples served as controls. Results: In the patient group, in comparison with the normal ranges, WT1 and VEGF gene expression was increased, the average values for the expression of these two genes being 0.2852±0.11 and 0.2029±0.018, respectively. While was no significant relevance between the two genes pre-treatment, a positive link between the two genes in 75% of patients with AML was noted during the procedure of chemotherapy, whereas in 75% of patients with ALL an antiparallel association was observed. Conclusions: Leukemia is associated with production of WT1, which may affect the expression of VEGF.

show abstract

“…While S-100 is also present in the nuclei, Vimentin is often absent in distant cell processes. The malignancy-associated expression of WT1 is less intense than in high-grade astrocytic lesions (Hashiba et al, 2007, Rushing et al, 2010 but usually more prominent as in reactive lesions or oligodendrogliomas. WT1 is expressed in 52% of all diffuse astrocytomas, but tumors with more than 75% positive WT1 cells should prompt the diagnosis of a high grade glioma (Schittenhelm et al, 2009).…”

Section: Immunohistochemistrymentioning

confidence: 93%

Diagnostic Evaluation of Diffuse Gliomas

Schittenhelm¹

2011

Advances in the Biology, Imaging and Therapies for Glioblastoma

View full text Add to dashboard Cite

Expression of WT1 Protein and Correlation With Cellular Proliferation in Glial Tumors

Cited by 49 publications

References 26 publications

Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma

Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma

Wilms' Tumor Gene (WT1) Expression Correlates with Vascular Epithelial Growth Factor (VEGF) in Newly Acute Leukemia Patients Undergoing Chemotherapy

Diagnostic Evaluation of Diffuse Gliomas

Contact Info

Product

Resources

About